Please assess the completion status of the following clinical trial:

Trial Title: Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal status defined as history of at least 12 months without spontaneous menstrual bleeding or a documented hysterectomy and bilateral salpingo oophorectomy~* Breast density greater than 25%~* No hormone replacement therapy for at least six months prior to entry into this study~* Non-smokers.~Exclusion Criteria:~* History of stroke, pulmonary embolism or deep vein thrombosis~* History of atherosclerotic heart disease~* Presence of any known hypercoagulable state either congenital (e.g., protein S deficiency) or acquired (e.g., corticosteroid treatment)~* Diabetes mellitus~* Uncontrolled hypertension (BP ≥140/90)~* Presence of a psychiatric condition that would interfere with adherence to the protocol.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: Control (Type: NO_INTERVENTION): Control, no intervention
- Group 2: Raloxifene 60 Mg Oral Tablet (Type: EXPERIMENTAL): Raloxifene 60 mg Orally Daily
- Group 3: Raloxifene 30 Mg Oral Tablet (Type: EXPERIMENTAL): Raloxifene 30 mg Orally Daily
- Group 4: Lovaza 4 gm oral (Type: EXPERIMENTAL): Lovaza 4 gm/day Orally with Meals
- Group 5: Lovaza 4gm & Raloxifene 30mg (Type: EXPERIMENTAL): Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily

Based on this trial design, predict the completion outcome and termination type (if applicable).